-+ 0.00%
-+ 0.00%
-+ 0.00%
Hanson Pharmaceuticals (03692): The marketing license for ametinib received positive opinions from the European Medicines Agency's Human Medicines Committee
Share
Listen to the news

Zhitong Financial App News, Hanson Pharmaceuticals (03692) announced that on November 12, 2026, the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP) adopted a positive opinion recommending that ametinib be granted marketing license to treat non-small cell lung cancer.



Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending